Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 93

1.

Prostate-Specific Membrane Antigen-Guided Surgery.

Maurer T, Graefen M, van der Poel H, Hamdy F, Briganti A, Eiber M, Wester HJ, van Leeuwen FWB.

J Nucl Med. 2020 Jan;61(1):6-12. doi: 10.2967/jnumed.119.232330. Epub 2019 Nov 15.

PMID:
31732677
2.

Diagnostic Accuracy of Ga-68-HBED-CC-PSMA-Ligand-PET/CT before Salvage Lymph Node Dissection for Recurrent Prostate Cancer.

Jilg CA, Drendel V, Rischke HC, Beck T, Vach W, Schaal K, Wetterauer U, Schultze-Seemann W, Meyer PT.

Theranostics. 2017 Apr 10;7(6):1770-1780. doi: 10.7150/thno.18421. eCollection 2017.

3.

Prostate-specific membrane antigen-guided salvage lymph node dissection in recurrent prostate cancer: a novel technology to detect lymph node metastases.

Maurer T, Gschwend JE, Eiber M.

Curr Opin Urol. 2018 Mar;28(2):191-196. doi: 10.1097/MOU.0000000000000458. Review.

PMID:
29028767
4.

Metastases-yield and Prostate-specific Antigen Kinetics Following Salvage Lymph Node Dissection for Prostate Cancer: A Comparison Between Conventional Surgical Approach and Prostate-specific Membrane Antigen-radioguided Surgery.

Knipper S, Tilki D, Mansholt J, Berliner C, Bernreuther C, Steuber T, Maurer T, Graefen M.

Eur Urol Focus. 2019 Jan;5(1):50-53. doi: 10.1016/j.euf.2018.09.014. Epub 2018 Oct 3.

PMID:
30292421
5.

Performance and Impact of Prostate Specific Membrane Antigen-Based Diagnostics in the Management of Men with Biochemical Recurrence of Prostate Cancer and its Role in Salvage Lymph Node Dissection.

Krimphove MJ, Theissen LH, Cole AP, Preisser F, Mandel PC, Chun FKH.

World J Mens Health. 2020 Jan;38(1):32-47. doi: 10.5534/wjmh.180133. Epub 2019 Mar 5. Review.

6.

99mTechnetium-based Prostate-specific Membrane Antigen-radioguided Surgery in Recurrent Prostate Cancer.

Maurer T, Robu S, Schottelius M, Schwamborn K, Rauscher I, van den Berg NS, van Leeuwen FWB, Haller B, Horn T, Heck MM, Gschwend JE, Schwaiger M, Wester HJ, Eiber M.

Eur Urol. 2019 Apr;75(4):659-666. doi: 10.1016/j.eururo.2018.03.013. Epub 2018 Apr 4.

PMID:
29625755
7.

High negative predictive value of 68Ga PSMA PET-CT for local lymph node metastases in high risk primary prostate cancer with histopathological correlation.

Rahman LA, Rutagengwa D, Lin P, Lin M, Yap J, Lai K, Mancuso P, Rathore P, Haghighi K, Gassner P, Wong LH, Lalak N.

Cancer Imaging. 2019 Dec 11;19(1):86. doi: 10.1186/s40644-019-0273-x.

8.

Prostate specific membrane antigen: the role in salvage lymph node dissection and radio-ligand therapy.

Ong WM, Zargar-Shoshtari K, Siva S, Zargar H.

Minerva Urol Nefrol. 2018 Oct;70(5):450-461. doi: 10.23736/S0393-2249.18.03152-1. Epub 2018 Jul 23. Review.

9.

Mapping prostate cancer lesions pre/post unsuccessful salvage lymph node dissection using repeat PSMA-PET.

Farolfi A, Ilhan H, Gafita A, Calais J, Barbato F, Weber M, Afshar-Oromieh A, Spohn F, Wetter A, Rischpler C, Hadaschik B, Pianori D, Fanti S, Haberkorn U, Eiber M, Herrmann K, Fendler WP.

J Nucl Med. 2019 Dec 5. pii: jnumed.119.235374. doi: 10.2967/jnumed.119.235374. [Epub ahead of print]

PMID:
31806773
10.

Patterns of Progression After 68Ga-PSMA-Ligand PET/CT-Guided Radiation Therapy for Recurrent Prostate Cancer.

Soldatov A, von Klot CAJ, Walacides D, Derlin T, Bengel FM, Ross TL, Wester HJ, Derlin K, Kuczyk MA, Christiansen H, Henkenberens C.

Int J Radiat Oncol Biol Phys. 2019 Jan 1;103(1):95-104. doi: 10.1016/j.ijrobp.2018.08.066. Epub 2018 Sep 7.

PMID:
30201438
11.

The Value of 99mTc-PSMA SPECT/CT-Guided Surgery for Identifying and Locating Lymph Node Metastasis in Prostate Cancer Patients.

Su HC, Zhu Y, Hu SL, Liu C, Lin GW, Dai B, Zhang YJ, Ye DW.

Ann Surg Oncol. 2019 Feb;26(2):653-659. doi: 10.1245/s10434-018-6805-y. Epub 2018 Oct 15.

PMID:
30324468
12.

Prostate-specific membrane antigen positron emission tomography/computed tomography combined with sentinel node biopsy for primary lymph node staging in prostate cancer.

Hinsenveld FJ, Wit EMK, van Leeuwen PJ, Brouwer OR, Donswijk ML, Tillier CN, Vegt E, van Muilekom HAM, van Oosterom MN, van Leeuwen FWB, van der Poel HG.

J Nucl Med. 2019 Sep 27. pii: jnumed.119.232199. doi: 10.2967/jnumed.119.232199. [Epub ahead of print]

PMID:
31562222
13.

Clinical impact of 68 Ga-prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) in patients with prostate cancer with rising prostate-specific antigen after treatment with curative intent: preliminary analysis of a multidisciplinary approach.

Albisinni S, Artigas C, Aoun F, Biaou I, Grosman J, Gil T, Hawaux E, Limani K, Otte FX, Peltier A, Sideris S, Sirtaine N, Flamen P, van Velthoven R.

BJU Int. 2017 Aug;120(2):197-203. doi: 10.1111/bju.13739. Epub 2017 Jan 4.

14.
15.

Value of 68Ga-PSMA HBED-CC PET for the Assessment of Lymph Node Metastases in Prostate Cancer Patients with Biochemical Recurrence: Comparison with Histopathology After Salvage Lymphadenectomy.

Rauscher I, Maurer T, Beer AJ, Graner FP, Haller B, Weirich G, Doherty A, Gschwend JE, Schwaiger M, Eiber M.

J Nucl Med. 2016 Nov;57(11):1713-1719. Epub 2016 Jun 3.

16.

Initial multicentre experience of 68 gallium-PSMA PET/CT guided robot-assisted salvage lymphadenectomy: acceptable safety profile but oncological benefit appears limited.

Siriwardana A, Thompson J, van Leeuwen PJ, Doig S, Kalsbeek A, Emmett L, Delprado W, Wong D, Samaratunga H, Haynes AM, Coughlin G, Stricker P.

BJU Int. 2017 Nov;120(5):673-681. doi: 10.1111/bju.13919. Epub 2017 Jun 20.

17.

68Ga-Labeled Prostate-specific Membrane Antigen Ligand Positron Emission Tomography/Computed Tomography for Prostate Cancer: A Systematic Review and Meta-analysis.

von Eyben FE, Picchio M, von Eyben R, Rhee H, Bauman G.

Eur Urol Focus. 2018 Sep;4(5):686-693. doi: 10.1016/j.euf.2016.11.002. Epub 2016 Nov 15.

18.

Single Lesion on Prostate-specific Membrane Antigen-ligand Positron Emission Tomography and Low Prostate-specific Antigen Are Prognostic Factors for a Favorable Biochemical Response to Prostate-specific Membrane Antigen-targeted Radioguided Surgery in Recurrent Prostate Cancer.

Horn T, Krönke M, Rauscher I, Haller B, Robu S, Wester HJ, Schottelius M, van Leeuwen FWB, van der Poel HG, Heck M, Gschwend JE, Weber W, Eiber M, Maurer T.

Eur Urol. 2019 Oct;76(4):517-523. doi: 10.1016/j.eururo.2019.03.045. Epub 2019 Apr 12.

PMID:
30987843
19.

Impact of 68Ga-PSMA-11 PET staging on clinical decision-making in patients with intermediate or high-risk prostate cancer.

Ferraro DA, Garcia Schüler HI, Muehlematter UJ, Eberli D, Müller J, Müller A, Gablinger R, Kranzbühler H, Omlin A, Kaufmann PA, Hermanns T, Burger IA.

Eur J Nucl Med Mol Imaging. 2019 Dec 4. doi: 10.1007/s00259-019-04568-1. [Epub ahead of print]

PMID:
31802175
20.

Value of 111 In-prostate-specific membrane antigen (PSMA)-radioguided surgery for salvage lymphadenectomy in recurrent prostate cancer: correlation with histopathology and clinical follow-up.

Rauscher I, Düwel C, Wirtz M, Schottelius M, Wester HJ, Schwamborn K, Haller B, Schwaiger M, Gschwend JE, Eiber M, Maurer T.

BJU Int. 2017 Jul;120(1):40-47. doi: 10.1111/bju.13713. Epub 2016 Dec 4.

Supplemental Content

Support Center